MoonLake Immunotherapeutics Fair Value Disclosure
(in thousands) | December 31, 2025 | December 31, 2024 | ||||||||||||
Level 2 | Total | Level 2 | Total | |||||||||||
Eurocommercial Papers | $ | — | $ | — | $ | 207,701 | $ | 207,701 | ||||||
Certificates of Deposit | 59,451 | 59,451 | 119,583 | 119,583 | ||||||||||
Total | $ | 59,451 | $ | 59,451 | $ | 327,284 | $ | 327,284 | ||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 25, 2026 | Showing above |
| 2024 | Feb 26, 2025 | |
| 2023 | Feb 29, 2024 | |
| 2022 | Mar 20, 2023 | |
| 2021 | Feb 17, 2022 | |
| 2020 | Mar 31, 2021 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.